PuraCath Medical Presents Study at National Kidney Foundation 2015 Spring Clinical Meetings

puracath • Mar 27, 2015

Company presents new data on the effectiveness of UV light to purify peritoneal dialysis catheter connections across a wider range of microorganisms that contribute to infections in PD patients

Dallas, Texas (March 27, 2015) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented new scientific data on its proprietary ultraviolet light-based technology during the National Kidney Foundation’s (NKF) 2015 Spring Clinical Meetings. The study presented reported on the ability to reduce bacterial growth in a simulated peritoneal dialysis delivery system when combining ultraviolet (UV) light with a UV transmissible connection system. This data confirms the effectiveness of combining UV light with a UV transmissible connection system to reduce bacterial growth across a wider range of bacteria and a fungi (Candida albicans) which are known to contribute to infections and peritonitis in peritoneal dialysis patients. The current study builds on earlier research the company presented at the American Society of Nephrology meeting in 2014.

“PuraCath Medical’s technology is a revolutionary approach to reducing the risk of infections that could lead to a change in the way peritoneal dialysis is performed,” stated Alberto Sabucedo, M.D., Ph.D., from the Department of Nephrology and Hypertension at the University of Miami. “This is a promising technology that will enable a better quality of life for patients on peritoneal dialysis, and I look forward to utilizing in my practice when it is available for clinical use.”

“While there is increasing interest in the use of peritoneal dialysis therapy to manage patients with end-stage renal disease, patients still currently remain at risk of developing infections and peritonitis from low compliance with rigorous disinfection protocols, impacting their ability to remain on this therapy for the long term,” said Julia Rasooly, PuraCath Medical’s CEO. “The study we presented at the NKF meeting confirms that our approach to reduce bacterial growth through the use of a novel UV light-based PD purification system is effective across a wider range of microorganisms than we initially tested. Based on the results of this study and the rapid progress we have made with our product development efforts to date, we look to initiate the first clinical studies of our technology in PD patients in the near future. PuraCath believes in the value and the lifestyle convenience peritoneal dialysis therapy offers to patients and we are developing a PD disinfection system that enhances PD patient’s quality of life and also provides an easy-to-use, patient friendly option to reducing bacterial and fungal contamination during PD exchanges. We feel confident that this will allow a broader range of patients to benefit from the quality of life of treatment on PD.”

WHAT IS PERITONEAL DIALYSIS?

Peritoneal dialysis is a home-based dialysis therapy that offers patients a more flexible and physiologically smoother dialysis option. Unlike hemodialysis, peritoneal dialysis uses a patient’s peritoneal membrane to remove toxins and excess fluid from a patient. Peritoneal dialysis therapy permits patients to have a more regular diet and more flexible treatment times, improving their quality of life. Currently there are over 45,000 peritoneal dialysis patients in the U.S. with the number of patients on this therapy increasing over the past several years. The most common complications from peritoneal dialysis include infection around the catheter site or infection of the lining of the abdominal wall (peritonitis).

ABOUT PURACATH MEDICAL

PuraCath Medical is a company based in San Francisco, CA and is dedicated to improving the quality of life for the dialysis patient by reducing infections related to peritoneal dialysis (PD) and saving time through improved, simplified connection of PD catheters. The Company utilizes technology that was spun out of Stanford University and is developing a novel, easy-to-use technology designed to reduce the risk of infections in patients with intravascular and peritoneal catheters in order to decrease infection-related hospitalizations and their associated costs.

For more information on PuraCath Medical, please visit www.puracath.com.

CONTACT
Julia Rasooly, M.S.
Founder and Chief Executive Officer
PuraCath Medical Inc.
+1.650.559.0388

PuraCath Medical Receives 510(k) Clearance for its Needleless Connector for Vascular Access
By puracath 03 Aug, 2021
Device is intended for use primarily by ICU nurses during infusions in patients in a critical care setting. PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has received 510(k) clearance for its FireFly™ Needleless Connector from the U.S. Food […]
Why We Aren’t Using UV to Disinfect Everything—Yet
By puracath 16 Jun, 2020
Negative perception and costs pose obstacles to a promising technology As the coronavirus pandemic continues, a technology that has existed for over 100 years is getting renewed attention as a promising disinfection tool. Ultraviolet germicidal radiation, which uses short-wavelength UV rays to kill bacteria and viruses, is already used to disinfect the air, water, and […]
PuraCath UV Device Displays a 99.9999% Disinfection of COVID-19 Virus in 1 Second
By puracath 27 Apr, 2020
PuraCath has been partnered and working with a top tier BSL-3 National Laboratory, which has a premiere high containment infectious disease facilities to test its Firefly UV device for the ICU and hospitals with 2019-nCoV (the COVID-19 virus). The preliminary results show that PuraCath’s device has achieved 99.9999% disinfection with SARS-CoV-2 (the virus that is […]
PuraCath FireflyTM Can Kill Deadly Microorganisms with UV Light, Like SARS CoV-2
By puracath 19 Mar, 2020
President Trump has officially declared a national emergency. A novel coronavirus has been identified in Wuhan City, China and has spread worldwide. It has been named SARS CoV-2 (causing disease COVID-19) by WHO. SARS CoV-2 has officially become a global pandemic by WHO. There have already been over 170,000 confirmed cases to date with an […]
By puracath 19 Jun, 2019
JUNE 18, 2019 PuraCath Medical, a venture-backed medical device company based in Silicon Valley, announced today that it has achieved 99.99% disinfection on its vascular access Firefly disinfection technology system with Candida auris (‘superbug’), Staphylococcus aureus, and Candida albicans. “Achieving greater than 4 log disinfection in these virulent microbes with only one second of UV […]
By puracath 07 Mar, 2017
San Francisco, California (March 7, 2017) – PuraCath Medical has published the result of its recent research on its ultraviolet (UV) light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the official Journal of the International Society for Peritoneal Dialysis. PDI is a major source of knowledge in the field of peritoneal dialysis and aims […]
PuraCath Medical to Present Data on FireFly™ Peritoneal Dialysis Connector Disinfecting System durin
By Larry Yost 12 May, 2016
San Francisco, California (May 12, 2016) – Data being presented will support planned introduction of PuraCath Medical’s technology in the European Union. PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it will present data on its next generation version of the FireFly™ […]
PuraCath Medical Presents Data at National Kidney Foundation 2016 Spring Clinical Meetings
By Larry Yost 28 Apr, 2016
Boston, Massachusetts (April 28, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of the FireFly™ Peritoneal Dialysis (PD) Connector Disinfecting System during the National Kidney Foundation’s 2016 Spring Clinical Meetings held […]
PuraCath Medical Presents New Research Data during 36th Annual Dialysis Conference
By Larry Yost 29 Feb, 2016
Company presents study on the effectiveness of next-generation version of the FireFly™ Peritoneal Dialysis Connector Disinfecting System Seattle, Washington (February 29, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of […]
PuraCath Medical Receives 510(k) Clearance for the FireFly™ Peritoneal Dialysis Connector Disinfecti
By puracath 26 Jan, 2016
PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it has received 510(k) clearance for its FireFly™ Peritoneal Dialysis Connector Disinfecting System from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives PuraCath clearance to market […]
More Posts
Share by: